Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening
Authors:
- Riley D. HellingerRHRiley D. Hellinger
- Keene L. AbbottKAKeene L. Abbott
- Khloe S. GordonKGKhloe S. Gordon
Preprint
Abstract
CAR-T therapy is a promising new treatment modality for B-cell malignancies. However, the majority of patients inevitably go on to experience disease relapse through largely unknown means. To investigate leukemia-intrinsic CAR-T resistance mechanisms, we performed genome-wide CRISPR-Cas9 loss-of-function screens in an immunocompetent murine model of B-cell acute lymphoblastic leukemia (B-ALL) utilizing a novel, modular guide RNA library. We identified IFNγ/JAK/STAT signaling and components of antigen processing and presentation pathway as key mediators of resistance to CAR-T therapy in vivo , but not in vitro . Transcriptional characterization of this model demonstrated an upregulation of these pathways in CAR-T treated relapsed tumors, and examination of data from CAR-T treated patients with B-ALL revealed an association between poor outcomes and increased expression of JAK/STAT/MHC-I in leukemia cells. Overall, our data identify an unexpected mechanism of resistance to CAR-T therapy in which tumor cell interaction with CAR-T cells in vivo induces expression of an adaptive T-cell resistance program in tumor cells.Keywords
This publication has 71 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- Positive Outcomes Influence the Rate and Time to Publication, but Not the Impact Factor of Publications of Clinical Trial ResultsPLOS ONE, 2013
- Natural killer cells act as rheostats modulating antiviral T cellsNature, 2011
- CD161-Expressing Human T CellsFrontiers in Immunology, 2011
- Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cellsBlood, 2010
- Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemiaGenes & Development, 2007
- Human NK Cell Education by Inhibitory Receptors for MHC Class IImmunity, 2006
- Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemiaProceedings of the National Academy of Sciences, 2006
- Retroviral Vectors for High-Level Transgene Expression in T LymphocytesHuman Gene Therapy, 2003
- Signalling through NK1.1 triggers NK cells to die but induces NK T cells to produce interleukin‐4Immunology, 1998